Christopher K. Fuller
University of California, Berkeley
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Christopher K. Fuller.
Archive | 2000
Christopher K. Fuller; Julie Hamilton; Harold D. Ackler; Peter Krulevitch; Bernhard E. Boser; Adam Eldredge; Frederick F. Becker; Jun Yang; Peter R. C. Gascoyne
We have developed a microfabricated flow-through impedance characterization system capable of performing AC, multi-frequency measurements on cells and other particles. The sensor measures both the resistive and reactive impedance of passing particles, at rates of up to 100 particles per second. Its operational bandwidth approaches 10 MHz with a signal-to-noise ratio of approximately 40 dB. Particle impedance is measured at three or more frequencies simultaneously, enabling the derivation of multiple particle parameters. This constitutes an improvement to the well-established technique of DC particle sizing via the Coulter Principle. Human peripheral blood granulocyte radius, membrane capacitance, and cytoplasmic conductivity were measured (r = 4.1 μm, Cmem = 0.9 μF/cm2, σint = 0.66 S/m) and were found to be consistent with published values.
Nature Methods | 2017
Peter Cameron; Christopher K. Fuller; Paul Daniel Donohoue; Brittnee N. Jones; Matthew S. Thompson; Matthew Merrill Carter; Scott Gradia; Bastien Vidal; Elizabeth Garner; Euan Slorach; Elaine Lau; Lynda M Banh; Alexandra M Lied; Leslie S Edwards; Alexander H. Settle; Daniel Capurso; Victor Llaca; Stéphane Deschamps; Mark Cigan; Joshua K. Young; Andrew May
RNA-guided CRISPR–Cas9 endonucleases are widely used for genome engineering, but our understanding of Cas9 specificity remains incomplete. Here, we developed a biochemical method (SITE-Seq), using Cas9 programmed with single-guide RNAs (sgRNAs), to identify the sequence of cut sites within genomic DNA. Cells edited with the same Cas9–sgRNA complexes are then assayed for mutations at each cut site using amplicon sequencing. We used SITE-Seq to examine Cas9 specificity with sgRNAs targeting the human genome. The number of sites identified depended on sgRNA sequence and nuclease concentration. Sites identified at lower concentrations showed a higher propensity for off-target mutations in cells. The list of off-target sites showing activity in cells was influenced by sgRNP delivery, cell type and duration of exposure to the nuclease. Collectively, our results underscore the utility of combining comprehensive biochemical identification of off-target sites with independent cell-based measurements of activity at those sites when assessing nuclease activity and specificity.
Archive | 2000
Peter A. Krulevitch; Harold D. Ackler; Frederick Becker; Bernhard E. Boser; Adam Eldredge; Christopher K. Fuller; Peter R. C. Gascoyne; Julie K. Hamilton; Stefan P. Swierkowski; Xiao-Bo Wang
Archive | 2001
Robin R. Miles; Amy W. Wang; Christopher K. Fuller; Asuncion V. Lemoff; Kerry A. Bettencourt; June Yu
Molecular Cell | 2016
Megan van Overbeek; Daniel Capurso; Matthew Merrill Carter; Matthew S. Thompson; Elizabeth Frias; Carsten Russ; John S. Reece-Hoyes; Christopher Nye; Scott Gradia; Bastien Vidal; Jiashun Zheng; Gregory R. Hoffman; Christopher K. Fuller; Andrew Paul May
Archive | 2000
Robin R. Miles; Kodumudi Venkateswaran; Christopher K. Fuller
Archive | 2004
Robin R. Miles; Phillip Belgrader; Christopher K. Fuller
Archive | 2000
Robin R. Miles; Kerry A. Bettencourt; Christopher K. Fuller
Nature Chemical Biology | 2009
Emma McCullagh; Justin Farlow; Christopher K. Fuller; Juliet Girard; Joanna Lipinski-Kruszka; Dan Lu; Thomas Noriega; Geoffrey Rollins; Russell Spitzer; Michael E. Todhunter; Hana El-Samad
International journal of advanced manufacturing systems | 2000
Jun Yang; Jody Vykoukal; Jamileh Noshari; Frederick F. Becker; Peter R. C. Gascoyne; Peter Krulevitch; Christopher K. Fuller; Harold D. Ackler; Julie Hamilton; Bernhard E. Boser; Adam Eldredge; Duncan Hitchens; Craig C. Andrews